Rockefeller Capital Management L.P. Trims Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Rockefeller Capital Management L.P. lessened its stake in IQVIA Holdings Inc. (NYSE:IQV) by 23.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 288,103 shares of the medical research company’s stock after selling 86,910 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in IQVIA were worth $56,622,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in IQV. Toronto Dominion Bank raised its stake in shares of IQVIA by 11.3% in the 3rd quarter. Toronto Dominion Bank now owns 60,416 shares of the medical research company’s stock valued at $14,317,000 after purchasing an additional 6,149 shares in the last quarter. TD Private Client Wealth LLC raised its stake in IQVIA by 8.4% during the third quarter. TD Private Client Wealth LLC now owns 1,031 shares of the medical research company’s stock valued at $244,000 after buying an additional 80 shares in the last quarter. Sanctuary Advisors LLC lifted its holdings in IQVIA by 60.8% during the 3rd quarter. Sanctuary Advisors LLC now owns 5,498 shares of the medical research company’s stock worth $1,303,000 after buying an additional 2,079 shares during the last quarter. World Investment Advisors LLC acquired a new position in shares of IQVIA in the 3rd quarter worth approximately $14,633,000. Finally, Arvest Bank Trust Division acquired a new stake in shares of IQVIA during the 3rd quarter valued at approximately $21,079,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

NYSE:IQV opened at $145.40 on Friday. IQVIA Holdings Inc. has a 52-week low of $135.97 and a 52-week high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market cap of $25.64 billion, a P/E ratio of 19.39, a PEG ratio of 1.99 and a beta of 1.46. The business’s 50-day moving average price is $182.32 and its 200 day moving average price is $199.64.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IQV has been the subject of several recent research reports. Stephens assumed coverage on shares of IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 target price for the company. Barclays reaffirmed an “equal weight” rating and set a $170.00 price objective (down previously from $235.00) on shares of IQVIA in a research report on Thursday. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. JPMorgan Chase & Co. dropped their price target on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. Finally, Citigroup lowered their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Six research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $241.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.